Insights Into Renal Cell Carcinoma (RCC) 2022
Perspectives on drivers in treatment decisions in the management of RCC
Select Report
Southeast/FL – February 10, 2022
Faculty Chair
Daniel J. George, MD
Duke Cancer Center, Durham, NC, USA
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of RCC
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
